Kingdon Capital Management L.L.C. Boosts Holdings in scPharmaceuticals, Inc. $SCPH

Key Points

• Kingdon Capital Management L.L.C. increased its stake in scPharmaceuticals by 25%, now holding 1,000,000 shares worth $2.63 million after acquiring an additional 200,000 shares.
• After several recent ratings changes, scPharmaceuticals has a consensus rating of "Hold" with an average target price of $12.00.
• scPharmaceuticals reported a quarterly loss of ($0.34) EPS, missing estimates, with revenue of $16.04 million that exceeded expectations of $15.41 million.

Kingdon Capital Management L.L.C. grew its stake in shares of scPharmaceuticals, Inc. (NASDAQ:SCPH - Free Report) by 25.0% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,000,000 shares of the company's stock after purchasing an additional 200,000 shares during the quarter. Kingdon Capital Management L.L.C. owned approximately 1.99% of scPharmaceuticals worth $2,630,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in SCPH. Assenagon Asset Management S.A. purchased a new position in scPharmaceuticals during the first quarter valued at approximately $33,000. Chicago Partners Investment Group LLC acquired a new stake in scPharmaceuticals during the 1st quarter worth about $31,000. ProShare Advisors LLC purchased a new stake in scPharmaceuticals in the fourth quarter valued at approximately $48,000. Price T Rowe Associates Inc. MD acquired a new stake in shares of scPharmaceuticals in the fourth quarter worth $54,000. Finally, Legato Capital Management LLC boosted its stake in shares of scPharmaceuticals by 48.1% in the first quarter. Legato Capital Management LLC now owns 15,275 shares of the company's stock worth $40,000 after buying an additional 4,961 shares during the last quarter. Institutional investors own 89.52% of the company's stock.

scPharmaceuticals Stock Performance

SCPH traded up $0.01 during trading on Tuesday, hitting $5.51. 2,475,767 shares of the stock were exchanged, compared to its average volume of 595,756. The stock has a fifty day moving average price of $4.78 and a two-hundred day moving average price of $3.66. scPharmaceuticals, Inc. has a 1-year low of $1.94 and a 1-year high of $6.28. The firm has a market capitalization of $293.68 million, a P/E ratio of -3.04 and a beta of 0.35. The company has a quick ratio of 3.14, a current ratio of 3.85 and a debt-to-equity ratio of 3.86.

scPharmaceuticals (NASDAQ:SCPH - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.04). The company had revenue of $16.04 million during the quarter, compared to analysts' expectations of $15.41 million. scPharmaceuticals had a negative net margin of 183.55% and a negative return on equity of 1,647.86%. As a group, sell-side analysts predict that scPharmaceuticals, Inc. will post -1.53 earnings per share for the current year.

Analyst Ratings Changes

Several research firms recently commented on SCPH. Wall Street Zen upgraded shares of scPharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday, August 9th. Craig Hallum lowered scPharmaceuticals from a "buy" rating to a "hold" rating and set a $6.00 price objective on the stock. in a report on Monday, August 25th. HC Wainwright cut scPharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Friday. Finally, Maxim Group lowered shares of scPharmaceuticals from a "buy" rating to a "hold" rating in a report on Monday, August 25th. Three equities research analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $12.00.

scPharmaceuticals Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.